These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
405 related articles for article (PubMed ID: 8722437)
1. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group. Davis BR; Cutler JA; Gordon DJ; Furberg CD; Wright JT; Cushman WC; Grimm RH; LaRosa J; Whelton PK; Perry HM; Alderman MH; Ford CE; Oparil S; Francis C; Proschan M; Pressel S; Black HR; Hawkins CM Am J Hypertens; 1996 Apr; 9(4 Pt 1):342-60. PubMed ID: 8722437 [TBL] [Abstract][Full Text] [Related]
2. Operational aspects of terminating the doxazosin arm of The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Pressel SL; Davis BR; Wright JT; Geraci TS; Kingry C; Ford CE; Piller LB; Bettencourt J; Kimmel B; Lusk C; Parks H; Simpson LM; Nwachuku C; Furberg CD; Control Clin Trials; 2001 Feb; 22(1):29-41. PubMed ID: 11165421 [TBL] [Abstract][Full Text] [Related]
3. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA; 2000 Apr; 283(15):1967-75. PubMed ID: 10789664 [TBL] [Abstract][Full Text] [Related]
4. Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Barzilay JI; Jones CL; Davis BR; Basile JN; Goff DC; Ciocon JO; Sweeney ME; Randall OS; Diabetes Care; 2001 Apr; 24(4):654-8. PubMed ID: 11315826 [TBL] [Abstract][Full Text] [Related]
5. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA; 2002 Dec; 288(23):2981-97. PubMed ID: 12479763 [TBL] [Abstract][Full Text] [Related]
6. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA; 2002 Dec; 288(23):2998-3007. PubMed ID: 12479764 [TBL] [Abstract][Full Text] [Related]
7. Participant recruitment in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Pressel S; Davis BR; Louis GT; Whelton P; Adrogue H; Egan D; Farber M; Payne G; Probstfield J; Ward H; Control Clin Trials; 2001 Dec; 22(6):674-86. PubMed ID: 11738123 [TBL] [Abstract][Full Text] [Related]
8. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Barzilay JI; Davis BR; Cutler JA; Pressel SL; Whelton PK; Basile J; Margolis KL; Ong ST; Sadler LS; Summerson J; Arch Intern Med; 2006 Nov; 166(20):2191-201. PubMed ID: 17101936 [TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Wright JT; Harris-Haywood S; Pressel S; Barzilay J; Baimbridge C; Bareis CJ; Basile JN; Black HR; Dart R; Gupta AK; Hamilton BP; Einhorn PT; Haywood LJ; Jafri SZ; Louis GT; Whelton PK; Scott CL; Simmons DL; Stanford C; Davis BR Arch Intern Med; 2008 Jan; 168(2):207-17. PubMed ID: 18227370 [TBL] [Abstract][Full Text] [Related]
10. Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). Haywood LJ; Ford CE; Crow RS; Davis BR; Massie BM; Einhorn PT; Williard A; J Am Coll Cardiol; 2009 Nov; 54(22):2023-31. PubMed ID: 19926008 [TBL] [Abstract][Full Text] [Related]
11. What ALLHAT tells us about treating high-risk patients with hypertension and hyperlipidemia. Geraci TS; Geraci SA J Cardiovasc Nurs; 2003; 18(5):389-95. PubMed ID: 14680343 [TBL] [Abstract][Full Text] [Related]
12. Effect of Statin Treatment vs Usual Care on Primary Cardiovascular Prevention Among Older Adults: The ALLHAT-LLT Randomized Clinical Trial. Han BH; Sutin D; Williamson JD; Davis BR; Piller LB; Pervin H; Pressel SL; Blaum CS; JAMA Intern Med; 2017 Jul; 177(7):955-965. PubMed ID: 28531241 [TBL] [Abstract][Full Text] [Related]
13. [Clinical study of the month. Which initial antihypertensive? Results from the ALLHAT trial]. Scheen AJ; Krzesinski JM Rev Med Liege; 2003 Jan; 58(1):47-52. PubMed ID: 12647599 [TBL] [Abstract][Full Text] [Related]
14. Coronary heart disease in moderately hypercholesterolemic, hypertensive black and non-black patients randomized to pravastatin versus usual care: the antihypertensive and lipid lowering to prevent heart attack trial (ALLHAT-LLT). Margolis KL; Dunn K; Simpson LM; Ford CE; Williamson JD; Gordon DJ; Einhorn PT; Probstfield JL; Am Heart J; 2009 Dec; 158(6):948-55. PubMed ID: 19958861 [TBL] [Abstract][Full Text] [Related]
15. Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group Hypertension; 2003 Sep; 42(3):239-46. PubMed ID: 12925554 [TBL] [Abstract][Full Text] [Related]
16. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis. Einhorn PT; Davis BR; Massie BM; Cushman WC; Piller LB; Simpson LM; Levy D; Nwachuku CE; Black HR; Am Heart J; 2007 Jan; 153(1):42-53. PubMed ID: 17174636 [TBL] [Abstract][Full Text] [Related]
17. Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Davis BR; Piller LB; Cutler JA; Furberg C; Dunn K; Franklin S; Goff D; Leenen F; Mohiuddin S; Papademetriou V; Proschan M; Ellsworth A; Golden J; Colon P; Crow R; Circulation; 2006 May; 113(18):2201-10. PubMed ID: 16651474 [TBL] [Abstract][Full Text] [Related]
18. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Rahman M; Pressel S; Davis BR; Nwachuku C; Wright JT; Whelton PK; Barzilay J; Batuman V; Eckfeldt JH; Farber M; Henriquez M; Kopyt N; Louis GT; Saklayen M; Stanford C; Walworth C; Ward H; Wiegmann T Arch Intern Med; 2005 Apr; 165(8):936-46. PubMed ID: 15851647 [TBL] [Abstract][Full Text] [Related]
19. Mortality and morbidity during and after Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: results by sex. Oparil S; Davis BR; Cushman WC; Ford CE; Furberg CD; Habib GB; Haywood LJ; Margolis K; Probstfield JL; Whelton PK; Wright JT; Hypertension; 2013 May; 61(5):977-86. PubMed ID: 23529173 [TBL] [Abstract][Full Text] [Related]
20. Influence of Prevalent and Incident Atrial Fibrillation on Post-Trial Major Events in ALLHAT. Haywood LJ; Davis BR; Piller LB; Cushman WC; Cutler JA; Ford CE; Simpson LM; Ghosh A; Soliman EZ; Wright JT; J Natl Med Assoc; 2017 Autumn; 109(3):172-181. PubMed ID: 28987246 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]